As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for samples received on April 20, at the Charlotte, Dallas, Phoenix, St. Louis and Tampa laboratories. Babesia is a selective pooled NAT test, required for all blood donations collected by May 2020, in 14 States and the District of Columbia. To help you understand the requirements, CTS will host a Babesia Implementation and Review webinar on March 3, 2020 at 11:00 am CST. If you are interested in attending, please contact your Customer Service Manager for invitation details.
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...